The estimated Net Worth of Stelios Papadopoulos is at least $262 Milione dollars as of 20 May 2024. Stelios Papadopoulos owns over 11,686 units of Biogen Inc stock worth over $253,245,466 and over the last 21 years he sold BIIB stock worth over $7,886,746. In addition, he makes $725,310 as Independent Chairman of the Board at Biogen Inc.
Stelios has made over 24 trades of the Biogen Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 11,686 units of BIIB stock worth $228,695 on 20 May 2024.
The largest trade he's ever made was buying 1,000,000 units of Biogen Inc stock on 25 July 2017 worth over $910,000. On average, Stelios trades about 44,431 units every 64 days since 2003. As of 20 May 2024 he still owns at least 1,272,015 units of Biogen Inc stock.
You can see the complete history of Stelios Papadopoulos stock trades at the bottom of the page.
Dr. Stelios B. Papadopoulos Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Papadopoulos has served as one of our directors since 2008 and as our independent Chairman since June 2014. Dr. Papadopoulos also serves as the Chairman of Regulus Therapeutics Inc., a biopharmaceutical company, and Exelixis, Inc., a drug discovery and development company that he co-founded in 1994. Previously, he was an investment banker with Cowen & Co., LLC, a financial services company, focusing on the biotechnology and pharmaceutical sectors, from 2000 until his retirement as Vice Chairman in August 2006. Prior to joining Cowen & Co., Dr. Papadopoulos served for 13 years as an investment banker at PaineWebber, Inc., a financial services company, where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Dr. Papadopoulos is also a director of BG Medicine, Inc., a diagnostics company focused on the development and commercialization of cardiovascular diagnostic tests. Having founded multiple life sciences companies and worked as an investment banker focused on the life sciences industry, Dr. Papadopoulos brings to our Board of Directors a firsthand understanding of the demands of establishing, growing and running life sciences businesses.
As the Independent Chairman of the Board of Biogen Inc, the total compensation of Stelios Papadopoulos at Biogen Inc is $725,310. There are 9 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Stelios Papadopoulos is 72, he's been the Independent Chairman of the Board of Biogen Inc since 2014. There are no older and 24 younger executives at Biogen Inc.
Stelios's mailing address filed with the SEC is C/O EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner e Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: